The ABCD prospective nationwide oral semaglutide audit is an independent audit supported by an unrestricted grant from Novo Nordisk Ltd

ABCD prospective nationwide oral semaglutide audit – follow-up visit data collection form



Date	/	/	(dd/mr	m/yyyy) Par	tient identifi	cation				
Name of clinician					Please r	ecord patient	name and dat	e of birt	h below	
Patient still taking oral se	maglutide?	Yes	No (circ	cle one)		— - AFFIX PA	ATIENT LABEL HE	RE		
If no:				 						
Date stopped	/	/	(dd/mm/	(yyyy)						
		choice Side effects Other (circle one)		P	Patient name					
Reason if 'other'			(22.2	=	ate of birth					
									(dd/mm/)	yyyy)
Test Results (test dates MUST HbA1c please enter eit		II tests where resul	Its are reported Date of test		Blood press	ure SRP	mmHg	Date of	tect	
or mmol/mol in corre		mmol/mol	Date of test		Blood press	DBP	mmHg	Date 01	test	
Of Hilliowhile in Control	occ cen	- Inmounted			Trial	lyceride	mmol/L	Date of	test	
Current v	veight	kg	Date of test			HDL	mmol/L	Date of		
BMI will be auto-calculated wh	nen data is enter	ed into audit spre	adsheet		Total cho	lesterol	mmol/L	Date of	test	
Alanine aminotransferas	e - ALT	IU/L	Date of test		Serum cre	eatinine	μmol/L	Date of	test	
Urine albumin: creatinine ratio mg/mmol (ACR)			Date of test]					
Current dose of oral sema	3 7 14 (circle one) mg/day						Adverse events should be reported. Reporting forms and			
GI side effects		No	(ence one)					information can be found at www.mhra.gov.uk/yellowcard.		
Other possible side effect	ts						(energ one)	be repo	events should rted to Novo No	ordisk
·								Nordisk 0845 60	(Telephone Nov Customer Care 05055). Calls ma itored for traini	Centre ay
Current medication:										
Metformin		Yes	No	Yes = 1; No=0)			Score		
Sulphonylurea		Yes	No		ax. dose max. dose – < full d	(Score 1) (Score 2) lose (Score 3) (Score 4)		Score		
Pioglitazone		0mg	15mg	30mg	45mg	No				
Meglitinides		Yes	No	Yes = 1; No=0)			Score		7
Alpha-glucosidase inhibitors		Yes	No	Yes = 1; No=0)			Score		<u>-</u> 1
SGLT2 inhibitors		Yes	No	Yes = 1; No=0)			Score		<u>-</u>]
DPP-4 inhibitors		Yes	No	Yes = 1; No=0)			Score		<u>-</u>]
Total dose of insulin				•				Total Dose		IU/day
Other antidiabetic medications or medications which could affect glycaemic control	S Drug name	(freetext box)								
Anti-obesity medication	Drug name	orlistat		Yes = 1; No=0)			Score		

ABCD prospective nationwide of the patient had a diabetic retinopath		ow-up visit data collection form (co	ontinued)		
Yes No Tick		If not known please enter best guess			
Result of screening					
Visual acuity: Left Eye Not known	6/6 6/9 6/12 6/18	6/24 6/36 6/48 6/60 6/CF 6/	HM 6/PL 6/NPL Circle one		
Right Eye Not known	6/6 6/9 6/12 6/18	6/24 6/36 6/48 6/60 6/CF 6/	HM 6/PL 6/NPL Circle one		
Retinopathy screening grade:					
Left Eye	Circle one	Right Eye	Circle one		
U - Ungradable	R2M1 Pre-proliferative diabetic	U - Ungradable	R2M1 Pre-proliferative diabetic		
NA - Unknown	retinopathy with maculopathy	NA - Unknown	retinopathy with maculopathy		
R0M0 No diabetic retinopathy R1M0 Background diabetic retinopathy	R3AM0 Acute proliferative retinopathy R3SM0 Stable proliferative retinopathy	R0M0 No diabetic retinopathy R1M0 Background diabetic retinopathy	R3AM0 Acute proliferative retinopathy R3SM0 Stable proliferative retinopathy		
R1M1 Background retinopathy	R3AM1 Acute proliferative	R1M1 Background retinopathy	R3AM1 Acute proliferative		
with maculopathy	retinopathy with maculopathy	with maculopathy	retinopathy with maculopathy		
R2M0 Pre-proliferative diabetic retinopathy	R3SM1 Stable proliferative retinopathy with maculopathy	R2M0 Pre-proliferative diabetic retinopathy	R3SM1 Stable proliferative retinopathy with maculopathy		
Exceeded expectation Achieved expectation Neither did nor did not achieve expectation (neutral) Did not achieve expectation Any other comments?	Tick one				